Luis Mora Capitán

Managing Director, Oncology Business Unit

Nadia Badri, M.D.

VP, Medical Strategy

Heiner Pieper

VP, Business Development & Licensing

Carmen Cuevas Marchante, Ph.D.

Director, Research & Development

Ana Belén Irigaray Huarte

Director, Regulatory Affairs

Juan Nogués Ortuño

Director, International Marketing and Sales

Pedro Berbil Bautista

Director, Industrial Operations

Luis Rupérez Cuenca

Director, Human Resources and IT

Elena Calleja Crespo

Director, Finance Oncology Business Unit

José Luis Ortega Conejero

Director, Quality Unit

Alfonso Ortín

Director, Communications

Pascal Besman

Chief Operating Officer of PharmaMar U.S.

Ali Zeaiter, M.D.

Director, Clinical Development

María Ángeles Forés, M.D.

Director, Medical Affairs

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.


If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.